Achilles Therapeutics plc (ACHL)
| Previous Close | 0.7990 |
| Open | 0.7901 |
| Bid | 0.7725 x 100 |
| Ask | 0.8078 x 200 |
| Day's Range | 0.7725 - 0.8300 |
| 52 Week Range | 0.7400 - 1.7600 |
| Volume | |
| Avg. Volume | 793,401 |
| Market Cap | 32.412M |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7400 |
| Earnings Date | May 08, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.83 |
GlobeNewswireAchilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company d
- GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company
Simply Wall St.Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
